Tag: cedirogant
Inventiva: stop the development of cedirogant – 10/31/2022 at 08:47
(CercleFinance.com) – Inventiva announces that AbbVie announced on Friday the discontinuation of the development of cedirogant (ABBV-157), discovered jointly by the two companies for the treatment of autoimmune diseases, following…
Inventiva: AbbVie stops developing a cedirogant for autoimmune diseases – 10/31/2022 at 08:48
(AOF) – Inventiva, a biopharmaceutical company, announced that AbbVie has announced the discontinuation of development of cedirogant (ABBV-157), an oral RORy inverse agonist jointly discovered by Inventiva and AbbVie for…
Inventiva: discontinuation of the development of cedirogant
(CercleFinance.com) – Inventiva announces that AbbVie announced on Friday the discontinuation of the development of cedirogant (ABBV-157), discovered jointly by the two companies for the treatment of autoimmune diseases, following…
Inventiva receives a €4 million milestone payment from AbbVie following the launch of the Phase IIb study with cedirogant – 01/31/2022 at 22:00
Daix (France), Long Island City (New York), United States, January 31, 2022 – Inventiva SA (“Inventiva” or the “Company”) (Euronext Paris and Nasdaq: IVA), a biopharmaceutical company specializing in the…
Inventiva receives a €4 million milestone payment from AbbVie following the launch of the Phase IIb study with cedirogant – 01/31/2022 at 22:00
Daix (France), Long Island City (New York), United States January 31, 2022 – Inventiva SA (“Inventiva” or the “Company”) (Euronext Paris and Nasdaq: IVA), a biopharmaceutical company specializing in the…